Double
Blind Study
UTILITY OF AN ORAL PRESENTATION OF hCG (human Choriogonadotropin)
FOR THE MANAGEMENT OF OBESITY.
A DOUBLE-BLIND STUDY (I)
Authors:
Dr. Daniel Oscar Belluscio, M.D.
Dr. Leonor Ripamonte, M.D
Dr. Marcelo Wolansky Ph.D
Correspondence
and questions :
Dr. Daniel Belluscio
Guido 1953
1119 Buenos Aires
Argentina
Phone And Fax: 0054-011-4804 97 84
Comments
CONTENTS
Abstract
Introduction
Materials
and methods
Procedures
Results
Discussion
Conclusions
Graphics
Photographies
Reference
Abstract
Female obese volunteers participating in a double blind study, and submitted
to the administration of an oral presentation of hCG (Human Choriogonadotropin)
plus a VLCD (Very Low Calorie Diet), decreased specific body circumferences
and skinfold thickness from conspicuous body areas more efficiently
than Placebo+VLCD -treated subjects.
Since a significant fat proportion from total body fat is subcutaneously located (50 to 65 percent, depending on sex and fat distribution), this hCG metabolic activity would result in a reduction of the total body fat mass, the main cause for obesity. We suggested that the combination of a VLCD and oral hCG could not only trigger clinically significant changes in subcutaneous fat stores but simultaneously decrease body weight and modelate body contour.
hCG
oral administration proved to be a safe and effective procedure on obese
treated volunteers. No side effects were observed in the course of the
study. There are no reports in the literature regarding this administration
route to compare our findings.
Compared to placebo treated subjects, volunteers managed with an oral
administration of hCG coped more efficiently with daily irritating situations,
were in a better mood, and handled home conflicts without stepping up
family discussions.
Download Full
Double Blind Study here
